Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction.

However, both genes are highly significant (p < 0.001, with log2FC values of 2.33 and 2.7, respectively) in SHGS+ versus SHGS- hepatocytes.

also in 132,142 other papers

The PPARα/γ agonist lanifibranor also showed a trend toward reducing SHGS in the GAN-MASH model, although this change did not reach statistical significance (Supplementary Fig. 6D ).

also in 53,322 other papers